Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6545080 | 0.86 | TSHR (0.42) | TSHRALDH1A1LMNA | |
| SCHEMBL6545278 | 0.82 | TSHR (0.38) | TSHR | |
| SCHEMBL7046887 | 0.81 | DGKA (0.50) | TSHRALDH1A1LMNA | |
| SCHEMBL4936173 | 0.81 | DGKA (0.50) | TSHRALDH1A1LMNA | |
| SCHEMBL1595383 | 0.81 | TSHR (0.44) | TSHRALDH1A1LMNA | |
| SCHEMBL31285293 | 0.81 | DGKA (0.50) | TSHRALDH1A1LMNA | |
| SCHEMBL27321456 | 0.81 | DGKA (0.39) | TSHRALDH1A1LMNA | |
| SCHEMBL8864847 | 0.80 | DUT (0.36) | TSHRALDH1A1LMNA | |
| SCHEMBL9626170 | 0.79 | ALDH1A1 (0.40) | TSHRALDH1A1LMNA | |
| SCHEMBL8865215 | 0.79 | DUT (0.35) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335792-B2 | Process for synthesizing aspartic and glutamic acid derivatives especially useful as intermediates in the manufacture of a caspase inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1436248-A2 | PROCESS FOR SYNTHESIZING ASPARTIC AND GLUTAMIC ACID DERIVATIVES AND DIAZOKETONE INTERMEDIATES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030162993-A1 | Process for synthesizing aspartic and glutamic acid derivatives especially useful as intermediates in the manufacture of a caspase inhibitor | VERTEX PHARMACEUTICALS INCORPORATED | 2003-08-28 | — | — | US | disclosed |
| WO-2003042169-A2 | PROCESS FOR SYNTHESIZING ASPARTIC AND GLUTAMIC ACID DERIVATIVES AND DIAZOKETONE INTERMEDIATES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162993-A1 | Process for synthesizing aspartic and glutamic acid derivatives especially useful as intermediates in the manufacture of a caspase inhibitor | CASP1, CASP5, CASP2 | TSHR 4797/4885ALDH1A1 2183/4885LMNA 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.